The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 01, 2024
Filed:
Jul. 30, 2020
Applicant:
Deciphera Pharmaceuticals, Llc, Waltham, MA (US);
Inventors:
Assignee:
Deciphera Pharmaceuticals, LLC, Waltham, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4375 (2006.01); A61K 31/4184 (2006.01); A61K 31/4439 (2006.01); A61K 31/4523 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 43/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4375 (2013.01); A61K 31/4184 (2013.01); A61K 31/4439 (2013.01); A61K 31/4523 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); A61P 43/00 (2018.01);
Abstract
The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.
Flynn, Daniel. (2024). Combination therapy for the treatment of mastocytosis (U.S. Patent No. 12102620). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12102620
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile